We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Enzyvant Draws Complete Response Letter for Rare Immunodeficiency Disorder
Enzyvant Draws Complete Response Letter for Rare Immunodeficiency Disorder
The FDA hit Enzyvant with a complete response letter for its regenerative tissue therapy RVT-802, an investigational drug for a rare immunodeficiency disorder.